Nine Diagnostics graduated from the BrightEdge accelerator program, culminating in a Demo Day presentation highlighting our progress building a nanosensor-enabled, machine learning-driven diagnostic platform for oncology. BrightEdge, the impact investment and innovation arm of the American Cancer Society, supports companies advancing innovations across prevention, detection, and treatment to improve cancer outcomes. Through the program, we benefited from structured mentorship and feedback on scientific strategy, clinical translation, and early go-to-market planning. The accelerator also helped strengthen our positioning within the oncology innovation ecosystem by connecting us with a network of operators, partners, and mission-aligned stakeholders focused on moving high-impact technologies from the lab toward real-world clinical adoption. Graduation from BrightEdge marks an important milestone in our company’s growth, reinforcing both the relevance of our approach and our momentum toward validation and deployment.
